AHCC,
does it really help with Immunity?
research showsAHCC has small human studies showing changes in immune-cell markers and a small randomized trial that looked at clearance of persistent HPV. However, broad immune clinical endpoints such as prevention of the common cold or influenza have not been confirmed, and the positive evidence is concentrated in the context of a specific product and manufacturer support.
ads claimAdvertisements mention 'NK cells,' 'immunity,' 'viral defense,' and 'adjunctive anticancer' effects. The verifiable human evidence remains limited to specific immune-cell markers and the narrow endpoint of persistent HPV.
Useful facts when choosing a product
- AHCC is not the same raw material as shiitake mushroom itself or lentinan.
- Representative research doses are often 3 g/day, and standardization differs substantially by product.
- Gastrointestinal symptoms, itching, and possible interactions with drug-metabolizing enzymes are mentioned.
- Use during cancer treatment should be considered separately from issues of treatment delay and interactions.
Chamgap Semantic Classification Code
Candidate index · review held
S.ahcc.UNK.immunity.assess.placeboSupplements and nutraceuticals > AHCC > Unknown > Immunity > Association or change assessment > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The Smith 2022 phase II RCT assigned 50 women with persistent high-risk HPV to AHCC 3 g/day or placebo and, after 6 months, reported a signal of HPV DNA/RNA negativity in 14/22 in the AHCC group versus 2/19 in the placebo group. The Yin 2010 healthy-adult study observed changes in the frequency of IFN-gamma/TNF-alpha-producing T cells after AHCC 3 g/day for 4 weeks, but this was not a clinical infection endpoint. Existing adjunctive cancer-care studies have major design and sample-size limits for generalizing to survival or infection prevention.
Why this is classified as C (49)
There is a signal from small human RCTs, so this is not D/?; however, general immunity claims depend on surrogate markers and specific product studies, so the grade is C, 49 points.
Counterpoint. In specific conditions such as persistent HPV, further research may be worthwhile, but that does not mean there is a general immune-enhancing effect.
Rejudgment record. Draft — There is a signal from small human RCTs, so this is not D/?; however, general immunity claims depend on surrogate markers and specific product studies, so the grade is C, 49 points.
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Smith JA et al. 2022 | Phase II randomized placebo-controlled trial | 50 | AHCC product supplied/possible product-company involvement | Clearance of persistent high-risk HPV | The HPV-negative conversion rate was higher in the AHCC group than in the placebo group. | Core |
| Yin Z et al. 2010 | Small human intervention study | Possible product-company involvement | Cytokine production by CD4/CD8 T cells | Changes in immune-cell surrogate markers were reported. | Supporting | |
| Memorial Sloan Kettering AHCC summary | Evidence summary | Independent medical institution | Efficacy and safety | It summarizes that clinical evidence is limited and that caution is needed when generalizing to adjunctive therapy. | Supporting |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-10).
Final verification and publication gate: Codex · Evidence date: 2026-07-10 · Corrections: none
Cite this verdict
[Chamgap] AHCC (active hexose correlated compound; shiitake mycelial extract) × Immunity — Evidence Grade C·49. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/ahcc-immune/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.